2001
Immunological Detection of a Novel Advanced Glycation End-Product
Takeuchi M, Yanase Y, Matsuura N, Yamagishi S, Kameda Y, Bucala R, Makita Z. Immunological Detection of a Novel Advanced Glycation End-Product. Molecular Medicine 2001, 7: 783-791. PMID: 11788793, PMCID: PMC1950006, DOI: 10.1007/bf03401969.Peer-Reviewed Original ResearchCharacterization of a Novel Hemoglobin-Glutathione Adduct That Is Elevated in Diabetic Patients
Al-Abed Y, VanPatten S, Li H, Lawson J, FitzGerald G, Manogue K, Bucala R. Characterization of a Novel Hemoglobin-Glutathione Adduct That Is Elevated in Diabetic Patients. Molecular Medicine 2001, 7: 619-623. PMID: 11778651, PMCID: PMC1950073, DOI: 10.1007/bf03401868.Peer-Reviewed Original ResearchConceptsDiabetic patientsDiabetes mellitusPredictor of prognosisBlood glucose levelsNormal patientsGlucose levelsPatientsUseful markerNormal individualsPathologic situationsOxidative stressMellitusAdditional markersΒ-globin chainsLiquid chromatography-mass spectroscopyΒ-chainMarkersHigh levelsPrognosisDiseaseDiagnosis
2000
Neurotoxicity of Advanced Glycation End-Products for Cultured Cortical Neurons
Takeuchi M, Bucala R, Suzuki T, Ohkubo T, Yamazaki M, Koike T, Kameda Y, Makita Z. Neurotoxicity of Advanced Glycation End-Products for Cultured Cortical Neurons. Journal Of Neuropathology & Experimental Neurology 2000, 59: 1094-1105. PMID: 11138929, DOI: 10.1093/jnen/59.12.1094.Peer-Reviewed Original ResearchConceptsCortical neuronsAge 2Alzheimer's diseaseEnd-stage renal diseaseNeuronal cellsAdvanced glycation end productsDM HD patientsGreater cytopathic effectsSpecific antibodiesAnti-AGE antibodyCultured cortical neuronsDose-dependent increaseGlycation end productsBlood of individualsCultured neuronal cellsDiabetes mellitusDiabetic patientsRenal diseaseNeurodegenerative processesNormal controlsAdvanced glycationCytopathic effectEpitope 1Cytotoxic effectsMTT assayImmunological Evidence that Non-carboxymethyllysine Advanced Glycation End-products Are Produced from Short Chain Sugars and Dicarbonyl Compounds in vivo
Takeuchi M, Makita Z, Bucala R, Suzuki T, Koike T, Kameda Y. Immunological Evidence that Non-carboxymethyllysine Advanced Glycation End-products Are Produced from Short Chain Sugars and Dicarbonyl Compounds in vivo. Molecular Medicine 2000, 6: 114-125. PMID: 10859028, PMCID: PMC1949938, DOI: 10.1007/bf03401779.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodiesCattleChromatography, AffinityCross ReactionsDiabetes Mellitus, Type 2Enzyme-Linked Immunosorbent AssayGlycation End Products, AdvancedGlyceraldehydeGlyoxalHumansImmunoblottingKidney Failure, ChronicLysineMaillard ReactionOxidation-ReductionPyruvaldehydeRabbitsRenal DialysisConceptsAGE antibodyCML-AGEDiabetic patientsAGE-bovine serum albuminShort Chain SugarsAdvanced glycation end productsAnti-AGE antibodyGlycation end productsAutoxidation of sugarsImmunization of rabbitsCML-BSADiabetic serumSerum albuminAdvanced glycationAGE contentSugar autoxidationRabbit serum albuminAGE modificationAntibodiesImmunological evidenceApparent molecular weightPatientsAge 3AgeImmunoblot analysis
1997
Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy
Koschinsky T, He C, Mitsuhashi T, Bucala R, Liu C, Buenting C, Heitmann K, Vlassara H. Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy. Proceedings Of The National Academy Of Sciences Of The United States Of America 1997, 94: 6474-6479. PMID: 9177242, PMCID: PMC21074, DOI: 10.1073/pnas.94.12.6474.Peer-Reviewed Original ResearchConceptsAdvanced glycation endproductsDietary advanced glycation endproductsEndogenous advanced glycation endproductsDiabetes mellitusKidney diseaseRenal excretionRenal vascular injuryDiabetic nephropathy patientsSerum AGE levelsDegree of albuminuriaNondiabetic kidney diseaseEnvironmental risk factorsAGE immunoreactivityRenal complicationsCreatinine clearanceDiabetic nephropathyNephropathy patientsRenal failureDiabetic patientsRisk factorsFood intakeHealthy subjectsGlycation endproductsDietary restrictionCL dietLipoprotein Modification by Advanced Glycosylation Endproducts (AGEs): Role in Atherosclerosis
Bucala R. Lipoprotein Modification by Advanced Glycosylation Endproducts (AGEs): Role in Atherosclerosis. Trends In Cardiovascular Medicine 1997, 7: 39-47. PMID: 21235862, DOI: 10.1016/s1050-1738(96)00137-5.Peer-Reviewed Original ResearchLow-density lipoproteinDiabetic patientsLDL levelsElevated LDL levelsEnzyme-linked immunosorbent assay (ELISA) techniqueRecent clinical observationsAdvanced glycosylation reactionsImmunosorbent assay (ELISA) techniqueVascular diseaseVascular pathologyVascular permeabilityNormal controlsClinical observationsAdvanced glycosylationLipoprotein depositionVascular wallClearance mechanismsNitric oxidePatientsRadical generating systemELISA analysisAgeLipoproteinOxidative modification
1996
What is the effect of hyperglycemia on atherogenesis and can it be reversed by aminoguanidine?
Bucala R. What is the effect of hyperglycemia on atherogenesis and can it be reversed by aminoguanidine? Diabetes Research And Clinical Practice 1996, 30: s123-s130. PMID: 8964186, DOI: 10.1016/s0168-8227(96)80048-9.Peer-Reviewed Original ResearchConceptsDiabetic patientsLDL levelsEndothelium-derived relaxing factorsElevated LDL levelsEffects of hyperglycemiaLow-density lipoproteinRelaxing factorsVascular diseaseVascular pathologyVascular permeabilityNormal controlsClinical observationsAdvanced glycosylationLipoprotein depositionVascular wallELISA techniqueClearance mechanismsNitric oxideClearance kineticsPatientsELISA analysisLDLAgeAminoguanidineLipoproteinSite-specific modification of apolipoprotein B by advanced glycosylation end-products: implications for lipoprotein clearance and atherogenesis
Bucala R. Site-specific modification of apolipoprotein B by advanced glycosylation end-products: implications for lipoprotein clearance and atherogenesis. Nephrology Dialysis Transplantation 1996, 11: 17-19. PMID: 9044301, DOI: 10.1093/ndt/11.supp5.17.Peer-Reviewed Original ResearchConceptsLDL receptorAGE modificationApolipoprotein BAdvanced glycosylationHuman fibroblast LDL receptorsAGE-modified formAGE-specific antibodiesRegion of apoBNon-diabetic individualsFibroblast LDL receptorLDL receptor binding siteRenal insufficiencyDiabetes mellitusDiabetic patientsElevated LDLAGE-LDLLipoprotein clearanceReceptor binding sitesHuman LDL receptorGeneral populationPlasma clearance kineticsTransgenic miceLDLAGE formationClearance kineticsThe role of advanced glycosylation end-products in the pathogenesis of atherosclerosis
Makita Z, Yanagisawa K, Kuwajima S, Bucala R, Vlassara H, Koike T. The role of advanced glycosylation end-products in the pathogenesis of atherosclerosis. Nephrology Dialysis Transplantation 1996, 11: 31-33. PMID: 9044304, DOI: 10.1093/ndt/11.supp5.31.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseLow-density lipoproteinDiabetic patientsDevelopment of atherosclerosisAGE-LDLAdvanced glycosylationAGE-modified formCoronary artery diseaseSerum total cholesterolPathogenesis of atherosclerosisArtery diseaseDiabetes mellitusRenal diseaseTotal cholesterolCerebrovascular diseaseMarked elevationRapid progressionTissue injuryVascular pathologyNormal controlsPatientsAGE-modified peptidesAtherogenic formAtherosclerosisAGE modification
1992
Hemoglobin-AGE: A Circulating Marker of Advanced Glycosylation
Makita Z, Vlassara H, Rayfield E, Cartwright K, Friedman E, Rodby R, Cerami A, Bucala R. Hemoglobin-AGE: A Circulating Marker of Advanced Glycosylation. Science 1992, 258: 651-653. PMID: 1411574, DOI: 10.1126/science.1411574.Peer-Reviewed Original ResearchConceptsAdvanced glycosylation end productsAdvanced glycosylationAGE-modified formAGE-specific antibodiesComplications of agingDiabetes-induced hyperglycemiaAge-related complicationsGlycosylation end productsCirculating MarkersDiabetic patientsRenal diseaseGlucose-derived Amadori productsNormal individualsComplicationsPatientsTissue modificationsTissue proteinsHemoglobinAmadori productsEnd productsPercentDiabeticsHyperglycemiaAtherosclerosisDiabetes